These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3154320)

  • 21. Loss of effectiveness of dihydralazine in the long-term treatment of chronic heart failure.
    Reifart N; Kaltenbach M; Bussmann WD
    Eur Heart J; 1984 Jul; 5(7):568-80. PubMed ID: 6479183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
    Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J
    Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
    Lang RM; Elkayam U; Yellen LG; Krauss D; McKelvie RS; Vaughan DE; Ney DE; Makris L; Chang PI
    J Am Coll Cardiol; 1997 Oct; 30(4):983-91. PubMed ID: 9316528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term therapy of chronic congestive heart failure with ibopamine: a multicenter trial.
    Rolandi E; Sabino F; Cantoni V; Ghirardi P; Marchetti GV; Cicchetti V
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S93-103. PubMed ID: 2483446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical results with prenalterol in patients with heart failure.
    Waagstein F; Reiz S; Ariniego R; Hjalmarson A
    Am Heart J; 1981 Sep; 102(3 Pt 2):548-54. PubMed ID: 7270401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of sulmazol on left ventricular function in congestive cardiomyopathy].
    Maurer E; Klein W; Brandt D
    Arzneimittelforschung; 1983; 33(5):760-3. PubMed ID: 6683555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Digitalis--friend or foe?
    Erdmann E
    Eur Heart J; 1995 Jul; 16 Suppl F():16-9. PubMed ID: 8521879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study].
    Assmann I; Kassel P; Duck HG; Fiehring H; Morgan P; Schmidt PK; Höfs T; Nehmiz G
    Z Kardiol; 1991 Nov; 80(11):687-94. PubMed ID: 1792811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Digoxin remains useful in the management of chronic heart failure.
    Dec GW
    Med Clin North Am; 2003 Mar; 87(2):317-37. PubMed ID: 12693728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
    Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D
    Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chronic therapy of congestive cardiomyopathy: effects of prenalterol and digoxin].
    Schwarz KR; Hofmann M; Mäurer W; Kadel C; von Olshausen K; Rauch B; Kübler W
    Z Kardiol; 1985 Jul; 74(7):374-83. PubMed ID: 3929486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
    Petein M; Levine TB; Cohn JN
    Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure.
    Ungar A; Fumagalli S; Marini M; Di Serio C; Tarantini F; Boncinelli L; Baldereschi G; Valoti P; La Cava G; Olianti C; Masotti G; Marchionni N
    Crit Care Med; 2004 May; 32(5):1125-9. PubMed ID: 15190961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.
    Maskin CS; Sinoway L; Chadwick B; Sonnenblick EH; Le Jemtel TH
    Circulation; 1983 May; 67(5):1065-70. PubMed ID: 6831672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular effects of a newly synthesized cardiotonic agent (TA-064) on normal and diseased hearts.
    Kino M; Hirota Y; Yamamoto S; Sawada K; Moriguchi M; Kotaka M; Kubo S; Kawamura K
    Am J Cardiol; 1983 Mar; 51(5):802-10. PubMed ID: 6829441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
    Kass DA; Van Anden E; Becker LC; Kasper EK; White WB; Feldman AM
    Am J Cardiol; 1996 Sep; 78(6):652-6. PubMed ID: 8831399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
    Feldman AM; Bristow MR; Parmley WW; Carson PE; Pepine CJ; Gilbert EM; Strobeck JE; Hendrix GH; Powers ER; Bain RP
    N Engl J Med; 1993 Jul; 329(3):149-55. PubMed ID: 8515787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
    Shakar SF; Abraham WT; Gilbert EM; Robertson AD; Lowes BD; Zisman LS; Ferguson DA; Bristow MR
    J Am Coll Cardiol; 1998 May; 31(6):1336-40. PubMed ID: 9581729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
    Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.